Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors

Gemcitabine based treatment is currently a standard first line treatment for patients with advanced pancreatic cancer, however overall survival remains poor, and few options are available for patients that fail gemcitabine based therapy. To identify potential molecular targets in gemcitabine refract...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Samulitis, Betty K, Pond, Kelvin W, Pond, Erika, Cress, Anne E, Patel, Hitendra, Wisner, Lee, Patel, Charmi, Dorr, Robert T, Landowski, Terry H
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2014
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623403/
https://ncbi.nlm.nih.gov/pubmed/25485960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.986967
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados